Results 41 to 50 of about 4,565 (192)

Personalized Medicine: Paradigm Shift in ALK Positive Non-Small Cell Lung Cancer: a Case Report [PDF]

, 2023
Background: Since the identification of multiple therapeutic targets, as is the case of anaplastic lymphoma kinase (ALK) translocation, the paradigm of treating patients with non-small cell lung cancer (NSCLC) has improved.
Barreira, JV, Leão Mendes, J, Parmanande, A   +2 more
core   +3 more sources

The emerging therapeutic landscape of alk inhibitors in non-small cell lung cancer [PDF]

, 2020
The treatment of metastatic non-small cell lung cancer (NSCLC) has undergone a paradigm shift over the last decade. Better molecular characterization of the disease has led to the rapid improvement of personalized medicine and the prompt delivery of ...
Bazan V., Galvano A., Gristina V., Iacono F., Mantia M. L., Russo A.   +5 more
core   +1 more source

Silibinin Overcomes EMT-Driven Lung Cancer Resistance to New-Generation ALK Inhibitors [PDF]

, 2022
Epithelial-to-mesenchymal transition (EMT) may drive the escape of ALK-rearranged non-small-cell lung cancer (NSCLC) tumors from ALK-tyrosine kinase inhibitors (TKIs).
Segura Carretero, Antonio, Verdura, Sara
core   +1 more source

Evaluation of the drug–drug interaction potential of brigatinib using a physiologically‐based pharmacokinetic modeling approach

CPT: Pharmacometrics & Systems Pharmacology
Brigatinib is an oral anaplastic lymphoma kinase (ALK) inhibitor approved for the treatment of ALK‐positive metastatic non‐small cell lung cancer. In vitro studies indicated that brigatinib is primarily metabolized by CYP2C8 and CYP3A4 and inhibits P‐gp,
Michael J. Hanley, Karen Rowland Yeo, Meera Tugnait, Shinji Iwasaki, Narayana Narasimhan, Pingkuan Zhang, Karthik Venkatakrishnan, Neeraj Gupta   +7 more
doaj   +1 more source

Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer

Frontiers in Public Health
BackgroundThe ALTA-1 L trial and EXP-3B arm of NCT01970865 trial found that both brigatinib and lorlatinib showed durable and robust responses in treating ALK-positive non-small cell lung cancer (NSCLC) patients.
Wenjie Liu, Wenjie Liu, Wenjie Liu, Wenjie Liu, Gengwei Huo, Gengwei Huo, Gengwei Huo, Gengwei Huo, Peng Chen, Peng Chen, Peng Chen, Peng Chen   +11 more
doaj   +1 more source

Difficulties on the acces to innovative targeted therapies for lung cancer in Spain [PDF]

, 2023
Purpose Spanish Lung Cancer Group (SLCG) conducted a review to analyze the barriers to access to innovative targeted therapies for non-small cell lung cancer (NSCLC) in clinical practice in Spain. Methods Review all relevant content published on websites
Calvo, Virginia, Camps, Carlos, Carcereny, Enric, Cobo, Manuel, Dómine, Manuel, García Campelo, María Rosario, González Larriba, José Luis, Guirado, María, Hernando-Trancho, Florentino, Massutí, Bartomeu, Nadal, Ernest, Provencio, Mariano, Rodríguez-Abreu, Delvys, Spanish Lung Cancer Group (SLCG/GECP), Sullivan, Ivana Gabriela, Sánchez, Alfredo   +15 more
core   +2 more sources

Protein glycosylation in lung cancer from a mass spectrometry perspective

Mass Spectrometry Reviews, EarlyView.
Abstract Lung cancer is a severe disease for which better diagnostic and therapeutic approaches are urgently needed. Increasing evidence implies that aberrant protein glycosylation plays a crucial role in the pathogenesis and progression of lung cancer.
Mirjam Balbisi, Simon Sugár, Lilla Turiák   +2 more
wiley   +1 more source

Sustained Improvement in the Management of Patients with Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocation: Where Are We Running?

Current Oncology, 2023
ALK translocation amounts to around 3–7% of all NSCLCs. The clinical features of ALK+ NSCLC are an adenocarcinoma histology, younger age, limited smoking history, and brain metastases.
Gianluca Spitaleri, Pamela Trillo Aliaga, Ilaria Attili, Ester Del Signore, Carla Corvaja, Chiara Corti, Edoardo Crimini, Antonio Passaro, Filippo de Marinis   +8 more
doaj   +1 more source

Advances and Future Perspectives for the Management of Non‐Small Cell Lung Cancer in Australia: A Narrative Review

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Lung cancer remains Australia's leading cause of cancer death. With new screening and evolving therapies, equitable access and workforce readiness are essential. This review discusses current and emerging treatments for NSCLC in Australia, clinical trials underway, and future directions in delivering optimal, accessible care nationwide.
Lauren Julia Brown, Graham Meredith, Bo Gao, Pei Ding, Harriet Gee, Inês Pires da Silva, Adnan Nagrial, Eric Hau   +7 more
wiley   +1 more source

Case Report: Durable Response to the Combination of Brigatinib and Cetuximab Plus Icotinib in a NSCLC Patient Harboring EGFR L858R-T790M-cis-G796S and L718Q Resistance Mutations Following Progression With Osimertinib

Frontiers in Oncology, 2022
The efficacy of osimertinib is severely limited by the emergence of EGFR C797S, which is detected in either the cis or trans position with T790M when osimertinib is used as a second-line treatment, and which is largely identified in combination with an ...
Yubo Wang, Rui Han, Mengxiao Zhu, Tingting He, Yong He   +4 more
doaj   +1 more source